Akrimax Pharmaceuticals has introduced Suprenza (phentermine HCl) orally disintegrating tablets (ODT) for the management of exogenous obesity.
The company has launched Suprenza ODT in 15mg and 30mg dosage strengths.
Suprenza is a sympathomimetic amine anorectic indicated for patients with an initial body mass index of greater than or equal to 30kg/m squared or greater than or equal to 27kg/m squared in the presence of other risk factors.
Akrimax corporate vice president and chief scientific officer Keith Rotenberg acknowledges findings from the US Centers for Disease Control and Prevention show that current statistics estimate over one third of the US population is overweight and another third of the population is obese.
"Suprenza provides physicians with a novel treatment alternative in the battle against obesity," Rotenberg added.
"Suprenza's unique formulation offers the patient the convenience of taking Suprenza with or without water and without regard to when the last meal was ingested."
